Paloma Partners Management Co lifted its stake in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 35.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,495 shares of the company’s stock after purchasing an additional 6,145 shares during the period. Paloma Partners Management Co’s holdings in Medidata Solutions were worth $1,489,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Polen Capital Management LLC purchased a new stake in shares of Medidata Solutions during the third quarter worth about $205,000. Hanseatic Management Services Inc. boosted its position in Medidata Solutions by 14,915.0% during the third quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock worth $234,000 after acquiring an additional 2,983 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Medidata Solutions by 48.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock worth $205,000 after acquiring an additional 1,056 shares during the last quarter. Zions Bancorporation acquired a new position in Medidata Solutions during the third quarter worth about $256,000. Finally, Brown Advisory Securities LLC acquired a new position in Medidata Solutions during the fourth quarter worth about $356,000. 97.52% of the stock is owned by institutional investors and hedge funds.
Medidata Solutions Inc (MDSO) opened at $67.20 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.19. The firm has a market cap of $4,018.38, a PE ratio of 77.98, a price-to-earnings-growth ratio of 3.57 and a beta of 1.56. Medidata Solutions Inc has a fifty-two week low of $54.91 and a fifty-two week high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $141.20 million for the quarter, compared to analyst estimates of $140.65 million. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. Medidata Solutions’s revenue was up 13.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.33 EPS. equities research analysts predict that Medidata Solutions Inc will post 0.93 earnings per share for the current fiscal year.
MDSO has been the topic of a number of recent research reports. TheStreet lowered shares of Medidata Solutions from a “b” rating to a “c+” rating in a research report on Thursday, December 14th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Wells Fargo & Co upgraded shares of Medidata Solutions from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research report on Friday, December 1st. Deutsche Bank initiated coverage on shares of Medidata Solutions in a research report on Friday, December 8th. They set a “buy” rating and a $78.00 price target on the stock. Finally, Morgan Stanley lowered their price target on shares of Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. Medidata Solutions presently has an average rating of “Buy” and a consensus target price of $82.07.
In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $66.46, for a total value of $132,920.00. Following the transaction, the chief financial officer now directly owns 87,775 shares in the company, valued at approximately $5,833,526.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Tarek Sherif sold 26,836 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $70.25, for a total transaction of $1,885,229.00. The disclosure for this sale can be found here. Insiders sold a total of 35,836 shares of company stock worth $2,494,989 over the last quarter. 5.80% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Paloma Partners Management Co Grows Stake in Medidata Solutions Inc (MDSO)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/16/paloma-partners-management-co-grows-stake-in-medidata-solutions-inc-mdso.html.
Medidata Solutions Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.